Cargando…
Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis
INTRODUCTION: Detection of serum biomarkers for early diagnosis of breast cancer remains an important goal. Changes in the structure of O-linked glycans occur in all breast cancers resulting in the expression of glycoproteins that are antigenically distinct. Indeed, the serum assay widely used for m...
Autores principales: | Blixt, Ola, Bueti, Deanna, Burford, Brian, Allen, Diane, Julien, Sylvain, Hollingsworth, Michael, Gammerman, Alex, Fentiman, Ian, Taylor-Papadimitriou, Joyce, Burchell, Joy M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219186/ https://www.ncbi.nlm.nih.gov/pubmed/21385452 http://dx.doi.org/10.1186/bcr2841 |
Ejemplares similares
-
Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer
por: Burford, B, et al.
Publicado: (2013) -
Latest developments in MUC1 immunotherapy
por: Taylor-Papadimitriou, Joyce, et al.
Publicado: (2018) -
Cancer-associated autoantibodies to MUC1 and MUC4—A blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening
por: Pedersen, Johannes W, et al.
Publicado: (2014) -
Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling)
por: Hanson, Ryan L., et al.
Publicado: (2016) -
Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas
por: Picco, Gianfranco, et al.
Publicado: (2014)